Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | PKD1 | P98161 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309634 | 0.95 | CTSB (0.58) | CTSBCTSSBACE1ALDH1A1LMNA | |
| SCHEMBL3309647 | 0.95 | CTSB (0.58) | CTSBCTSSBACE1ALDH1A1LMNA | |
| SCHEMBL13330964 | 0.95 | CTSB (0.58) | CTSBCTSSBACE1ALDH1A1LMNA | |
| SCHEMBL3304494 | 0.93 | CTSB (0.57) | CTSBCTSSALDH1A1LMNAMAPT | |
| SCHEMBL13330965 | 0.89 | CTSB (0.72) | CTSBCTSS | |
| SCHEMBL13330966 | 0.89 | CTSB (0.61) | CTSBCTSS | |
| SCHEMBL8172705 | 0.89 | CTSB (0.59) | CTSBCTSSMAPTKMT2A | |
| SCHEMBL3309952 | 0.89 | CTSB (0.59) | CTSBCTSSMAPTKMT2A | |
| SCHEMBL3309943 | 0.89 | CTSB (0.59) | CTSBCTSSMAPTKMT2A | |
| SCHEMBL3315198 | 0.87 | CTSB (0.58) | CTSBCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | CTSB 2141/4885CTSS 1936/4885BACE1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.